Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Go back to Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer| AGENUS (NASDAQ: AGEN) | Delayed: 7.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.43 | 52 Week High | $7.49 | |||
| Open | $7.43 | 52 Week Low | $2.61 | |||
| Day High | $7.43 | P/E | N/A | |||
| Day Low | $7.43 | EPS | $-1.10 | |||
| Volume | 95 | |||||
| (NASDAQ: INKT) | Delayed: 11.45 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.45 | 52 Week High | $ | |||
| Open | $11.45 | 52 Week Low | $ | |||
| Day High | $11.45 | P/E | N/A | |||
| Day Low | $11.45 | EPS | $ | |||
| Volume | 2,480 | |||||
